CBD Life Sciences, Inc. (CBDL) Debuts Kratom for Treatment of Pain and Opioid Withdrawal
Ryan Allway
October 13th, 2021
News
SCOTTSDALE, AZ / ACCESSWIRE / October 13, 2021 / Today CBD Life Sciences (OTC PINK:CBDL) through its wholly owned subsidiary, LBC Bioscience Inc. announces that the company is yet again expanding its product line with Kratom, which is an outstanding addition to the already stacked list of products.
CBD Life Sciences Inc. is currently working with various kinds of Kratom based upon certain specific benefits. This product will be coming live to the LBC website along with eBay, Amazon, and Alibaba within a couple of weeks. The jar will contain 75 capsules and each capsule will contain 500MG. President & CEO Lisa Nelson states “By adding this product to our shelves, it will open up doors to many different kinds of customers and it is becoming more and more known, so I think we got our hands on it at the exact right time!” Lisa Nelson also states, “As a medicine, kratom is used for anxiety, cough, depression, diabetes, diarrhea, high blood pressure, pain, to improve sexual performance, and to lessen symptoms of opiate withdrawal.”
What is Kratom?
Kratom is the name of a tree from the coffee family native to Southeast Asia. Also known as mitragyna speciosa, it is grown in Thailand, Malaysia, and Indonesia. Its leaves are dried and used to make tea or encapsulated and sold as a supplement. Kratom leaves can also be smoked like tobacco. The most common uses of it are to relieve pain, depression, and opioid addiction. The two most active compounds found in kratom, mitragynine and 7-hydroxymitragynine, work on opioid receptors, but with fewer side effects. Kratom has been used for hundreds of years in Asia as a natural home remedy. Traditionally, it has been used to treat Fatigue, Pain, Diarrhea, and Muscle Cramps.
Survey
A 2015 study in Thailand that reported that people in Asia have been using kratom successfully to treat opioid addiction for decades renewed interest among researchers in the U.S.
For the current survey, a company and their team enrolled 2,798 people to complete an online survey on their use of kratom. They recruited participants online and through social media, as well as through the AKA. Overall, users were mostly white, educated, and middle-aged. Some 61% of users were women, and 90% were white. About 6% reported being multiracial, 1.5% reported being Native American or Hawaiian, 0.5% reported being Asian and 0.4% said they were African American. Participants were an average age of 40. About 84% of participants reported having at least some college education.
Of these participants, 91% reported taking kratom to alleviate pain on average a couple times a day for back, shoulder and knee pain, 67% for anxiety and 65% for depression. About 41% of survey responders said they took kratom to treat opioid withdrawal, and of those people who took it for opioid withdrawal, 35% reported going more than a year without taking prescription opioids or heroin.
As part of the survey, participants completed a Substance Use Disorder Symptom checklist to assess whether their use qualified as a substance use disorder according to the American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition guidelines. Fewer than 3% of responses met the criteria for moderate or severe substance use disorder for abusing kratom, but about 13% met some criteria for kratom-related substance use disorder. This is comparable to about 8%-12% of people prescribed opioid medications who became dependent, according to statistics from the U.S. National Institute for Drug Abuse (NIDA).
CBD Life Sciences Inc. is getting close to its 3rd retail location along with a recreational marijuana facility. This will be significant as far as expansion and revenue go and CBD Life Sciences Inc. will keep the public informed moving forward.
The number of benefits CBD has is tremendous! These benefits may help with behavioral/neurological complications such as ADD/ADHD, anxiety, autism, bipolar, OCD, PTSD, epilepsy, Parkinson’s, osteoporosis, and ALS. CBD may also benefit pain management that can stem from headaches/migraines, arthritis, cramps, spinal injuries, and fibromyalgia. CBD has been found to also have gastrointestinal benefits with gastro-disorders and complications such as anorexia, cachexia, Crohn’s, diabetes, and nausea. Physical complications/disorders such as muscular dystrophy and even immune system-based deficiencies and other complications such as cancer and hypertension even our bodies way and ability to maintain homeostasis have all been said to benefit from CBD.
LBC BIOSCIENCE INC. ONLINE STORE
LBC BIOSCIENCE’S Online Emporium
LBC Bioscience Inc. is well stocked already as it is with some very high-quality CBD offerings – all at very reasonable prices. Check out LBC Bioscience Inc’s newest product offerings including its: 100MG CBD Bath Bombs in a variety of scents, Delta 8 Gummies, 1500 MG Premium Berry Drops, and a variety of all-new Skincare products. Or shop our top selling products (based on order frequency) which include our CBD Pain Cream, CBD Oils and CBD Pet Treats.
- Large Selection of Products (over 50 items and growing)
- 100% USA Made Products “organic & kosher.”
- All Products are THC-FREE (they contain 0.00% THC)
- Weekly Deals (new deals every week)
- 25% off on all products using code “LBC25.”
LBC Bioscience Inc. accepts: Visa, MasterCard, American Express, Discover etc.
Shareholders and interest holders may also stay current with LBC Bioscience Inc Updates:
LBC Bioscience Inc’s Main Website at www.lbcbioscienceinc.com
Twitter: https://www.twitter.com/lbcbioscience
Facebook: https://www.facebook.com/lbcbioscience
Instagram: https://www.instagram.com/lbcbioscience
Amazon: https://www.amazon.com/shops/lbcbioscienceinc
eBay: https://www.ebay.com/usr/lbcbioscience
Alibaba: https://lbcbioscience.trustpass.alibaba.com/
About LBC Bioscience Inc.
LBC Bioscience Inc. is a wholly owned subsidiary of CBD Life Sciences Inc. LBC has developed and is retailing/wholesale a full line of cannabidiol based organic products including CBD Drops, Gumballs, Honey Sticks, Pain Relief Creams, Anxiety & Sleep Supplements, Edibles, Coffee, Skincare Line, Pet Line, Tablets and more. LBC’s products can be viewed and purchased on the Company’s website at www.lbcbioscienceinc.com.
Ten Associates LLC
Contact: Thomas E. Nelson
Telephone: (480) 326-8577
Email: tenassociates33@gmail.com
Website: www.tenassociatesllc.com
Forward-Looking Statements
Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties. See CBD Life Sciences, Inc’s, Inc.’s filings with OTC Markets, which may identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.
Safe Harbor Statement
This release includes forward-looking statements, which are based on certain assumptions and reflects management’s current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include: general global economic conditions; general industry and market conditions, sector changes and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, including codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking
SOURCE: CBD Life Sciences Inc.
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
About Ryan Allway
Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.
Search CannabisFN
Press Coverage
Psychedelics Index
Top Videos
The producers of O’ Cannabiz have decades of experience producing national-profile events and creating global connections between business communities in the arts, broadcasting, media and technology. They have organized trade summit initiatives with governments around the world. And they have worked closely with sponsors in all levels of Canadian government.
Rob is the co-founding President of Pelorus Equity Group and has more than 18 years of experience in the real estate finance industry. Since the formation of Pelorus in 2010, he has raised more than $175,000,000 in secured real estate transactions. Rob’s primary role at Pelorus Equity Group is the development of strategic alliances with […]
JWC is a Licensed Producer under the ACMPR with the goal of helping patients by providing clean, consistent medical cannabis products.
Plus Products, through its wholly-owned subsidiary, Carberry, operates as a branded cannabis products manufacturer with operations in California.
Network Partners
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.
Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer
